In addition, considering the pre-treatment CD4pos cell phenotype, early RA patients with pre-treatment enrichment of CD4posCD25posFoxP3pos rates (≥ 6.0%) among peripheral blood-derived CD4pos cells, had the highest chance of DAS remission achievement at 6 months of CTLA4-Ig treatment. Here, CTLA4 is linked to rheumatoid arthritis.